Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0513 • ACR Convergence 2024
Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting
Ioasaf Karafotias¹, Maryam Adas¹, Katie Bechman¹, Nicholas Williamson¹, Mark Hughes¹, Daksh Mehta², Ritika Roy¹, Sam Norton³ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³King's College London, London, England, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-positive B cells and is used to treat rheumatoid arthritis (RA). B cell depletion may result in hypogammaglobulinemia. Hypogammaglobulinemia is a risk…
Abstract Number: 0531 • ACR Convergence 2024
Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort
Sama Hajizadeh¹, Tyson Barrett², Yue Yin³ and Dr Tarun Sharma⁴, ¹Allegheny Health Network, Pittsburgh, ²Enterprise Data and Analytics, Highmark Health, Pittsburgh, ³Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, ⁴West Penn Hospital, Pittsburgh, PA
Background/Purpose: Existing American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) guidelines regarding medication tapering in patients with rheumatoid arthritis (RA)…
Abstract Number: 0802 • ACR Convergence 2024
Disease Activity Is Strongly Associated with RA-related Lung Disease and Interstitial Lung Disease in Early RA: Results from a Multicenter, Prospective Cohort Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Xiaosong Wang⁴, Misti Paudel⁵, Emily Kowalski³, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni³, Caleb Bolden⁶, Tina Mahajan⁷, Erica Mulcaire-Jones⁸, Neda Kortam⁸, Pierre-Antoine Juge⁹, Tracy J Doyle¹⁰, Zachary Wallace¹¹, Marcy Bolster⁶, Kevin Deane¹², Dinesh Khanna⁸, Bryant England⁷ and Jeffrey Sparks¹³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁶Massachusetts General Hospital, Boston, MA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸University of Michigan, Ann Arbor, MI, ⁹Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ¹⁰Brigham and Women's Hospital, West Roxbury, MA, ¹¹Massachusetts General Hospital, Newton, MA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of lung disease including interstitial lung disease (ILD), bronchiectasis, and emphysema. Risk factors for the development and progression…
Abstract Number: 0896 • ACR Convergence 2024
Identification of Immune Pathways Regulated by a Non-Coding Variant at DNASE1L3/PXK/PDHB
Michelle Morency¹, Taehyeung Kim¹ and Peter Nigrovic², ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis (RA) is a prevalent autoimmune disease in which aberrant immune attacks on joints and other tissues leads to permanent and disabling injury.…
Abstract Number: 0947 • ACR Convergence 2024
REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis
Alexandra Gardino¹, Neil Bifulco¹, Jeremy Hunt², Rishi Vaswani¹, Donglim Park², Patrick Metz², Ksenya Cohen-Katsenelson², Jeong-Ho Kim², Xia Tian², Aryan Alavi², Ajay Nirula², Daniel Treiber², Brian Hodous¹, Seong Kim³ and Paul Smith², ¹Recludix Pharma, Cambridge, MA, ²Recludix Pharma, San Diego, CA, ³Department of Microbiology and Immunology, LSU Health Shreveport, Shreveport, LA
Background/Purpose: Inhibition of JAK family signaling has translated into clinically meaningful efficacy in rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. However, small molecule JAK/TYK2…
Abstract Number: 1015 • ACR Convergence 2024
Performance of a Molecular Signal Response Classifier Predicting Inadequate Response to Tumor Necrosis Factor Inhibitors in Hispanic Patients with Rheumatoid Arthritis
Viet Bui¹, Miguel Rodriguez² and Sarah Ormseth³, ¹Harbor UCLA Medical Center and The Lundquist Institute, Torrance, CA, ²Texas Arthritis Center, El Paso, TX, ³The Lundquist Institute, Torrance, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 1075 • ACR Convergence 2024
Optimizing Herpes Zoster Vaccination in Rheumatoid Arthritis Patients Ages 18-49 Years: A Quality Improvement Approach
Akhil Sood¹, Pegah Jahangiri¹, Christy Bill² and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford Health Care, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis are at increased risk for Herpes Zoster (HZ) infection, which is associated with increased hospitalizations and healthcare resource utilization. Despite…
Abstract Number: 1329 • ACR Convergence 2024
Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty
Stephen Batter¹, Huong Do¹, Dongmei Sun², Ahmed Deeb¹, Trang Bui¹, Jason Blevins¹, Mark Figgie¹, Gwo-Chin Lee¹, J. Alex B. Gibbons³, Bella Mehta⁴, Susan Goodman⁵ and Linda A Russell¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Birmingham, AL, ³Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Use of ambulatory surgery in arthroplasty is increasing, but the need for transfusion mandates hospital admission. Despite the significant drop in transfusion rate linked…
Abstract Number: 1345 • ACR Convergence 2024
Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study
Cristina Corrales Selaya¹, Nuria Vegas Revenga², Carmen Secada Gómez³, Jose Antonio parra-Blanco⁴, Virginia Portilla-González⁴, Ricardo Blanco-Alonso⁵, Miguel Angel Gonzalez-Gay⁶, ivan Ferraz-Amaro⁷ and alfonso Corrales-Martínez⁸, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Hospital Galdakao- Usansolo, Galdakao, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of subclinical cardiovascular (CV) disease and, consequently, a higher incidence of CV events, compared to the…
Abstract Number: 1361 • ACR Convergence 2024
The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis
George Karpouzas¹, Virginia Pascual Ramos², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Piet Van RIel¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Radboud University Medical Center, Nijmegen, Netherlands, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Rheumatoid arthritis (RA) activity associates with cardiovascular (CV) risk. Anticitrullinated protein antibodies (ACPA) were linked to higher activity and lower remission rates. Treatment responses…
Abstract Number: 1377 • ACR Convergence 2024
Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
Adrián Quevedo-Rodríguez¹, Lucia Otero-Varela², Fernando Sánchez-Alonso³, Yanira Pérez-Vera¹, Javier Manero-Ruiz⁴, Cristina Campos-Fernández⁵, Sara Manrique-Arija⁶, Paloma Vela-Casasempere⁷, Antonio Mera-Varela⁸, César Díaz⁹, Atusa Movasat¹⁰, Blanca Garcia-Magallon¹¹, Inmaculada Ros-Vilamajó¹², Carolina Perez-Garcia¹³ and Isabel Castrejon¹⁴, and BIOBADASER working group., ¹Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Spain, ⁴Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁵Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ⁶Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁷Hospital General Universitario Alicante, Alicante, Spain, ⁸Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Universitario Príncipe de Asturias, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ¹²Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain
Background/Purpose: Biologic and targeted synthetic disease-modifying drugs (b/tsDMARDs) have changed the way rheumatoid arthritis (RA) is managed in recent years. Still, some patients remain symptomatic…
Abstract Number: 1394 • ACR Convergence 2024
Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
Yurilu Gonzalez Moret¹, Diego Lema² and Fabian Rodriguez Quinonez³, ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, ³Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) are a class of disease activity-modifying drugs (DMARDs) that have quickly established a role in managing rheumatoid arthritis. Inhibition of…
Abstract Number: 1662 • ACR Convergence 2024
Using Circulating Soluble Serum Mediator Profiles to Understand the Mechanisms Driving Disease Flare and Drug-free Remission in Rheumatoid Arthritis
Amy Anderson¹, Fiona Rayner², Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Jasmine Sim¹, Andrew Melville³, Stefan Siebert³, Iain McInnes⁴, Carl Goodyear³, Catharien Hilkens¹, Andrew Filer⁵, Karim Raza⁵, Christopher Buckley⁶, Kenneth Baker¹, Arthur Pratt² and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ³School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁵Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁶Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Little is known of the factors that trigger disease relapses/flares in patients with rheumatoid arthritis (RA). The underpinning mechanisms have been difficult to study…
Abstract Number: 1744 • ACR Convergence 2024
Artificial Intelligence: A Novel Tool in the Belt for Improving Rheumatoid Arthritis Outcomes in the National Health Service, United Kingdom
Urwah Ahmed¹, Katharine Kalap² and Hilary Johnson³, ¹Gloucestershire Hospitals NHS Foundation Trust, Aylesbury, United Kingdom, ²Princeton University, Princeton, ³Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
Background/Purpose: Earlier diagnosis and treatment of Rheumatoid Arthritis (RA) improve patient outcomes including pain, disability and overall mortality (NICE, 2024). The National Institute for Health…
Abstract Number: 1874 • ACR Convergence 2024
Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort
Fabio Cacciapaglia¹, Gian Luca Erre², Matteo Piga³, Elena Bartoloni Bocci⁴, Andreina Manfredi⁵, Ennio Giulio Favalli⁶, Maria Sole Chimenti⁷, Serena Guiducci⁸, Eleonora Celletti⁹, Addolorata Corrado¹⁰, Alessandro Giollo¹¹, SIMONE PARISI¹², Ivan Giovannini¹³, Elisa Gremese¹⁴, Francesca Romana Spinelli¹⁵, Garifallia Sakellariou¹⁶, Ombretta Viapiana¹⁷ and Fabiola Atzeni¹⁸, and Cardiovascular Obesity and Rheumatic DISeases Study Group of the Italian Society of Rheumatology, ¹Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Rheumatology Unit - University of Sassari, Sassari, Italy, ³Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁴Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁵University of Modena and Reggio Emilia, Modena, ⁶ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ⁷Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ⁸University of Florence, Pistoia, Italy, ⁹Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹⁰Rheumatology Unit, University of Foggia, Foggia, Italy, ¹¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ¹²Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁵Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁶Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ¹⁷Rheumatology Unit, University of Verona, Verona, Italy, ¹⁸University of Messina, Italy, Messina, Italy
Background/Purpose: This study aimed to compare the performance of three validated algorithms for 10-year global cardiovascular risk stratification (GCVR): the European Systemic Coronary Risk (SCORE-2)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].